About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Drug To Treat Low-grade Ovarian Cancer Found

by VR Sreeraman on February 15, 2013 at 7:37 PM
Font : A-A+

 New Drug To Treat Low-grade Ovarian Cancer Found

Researchers have discovered that taking a regular dose of the compound selumetinib help stabilize or shrink tumors in women with low-grade serous carcinoma of the ovary or peritoneum.

The findings show that selumetinib targets a mutation in the MAPK pathway for patients with low-grade serous carcinoma, allowing for treatment on previously chemoresistant tumors.

Advertisement

"This is a potentially important breakthrough for the Gynecologic Oncology Group," said John Farley, MD, a gynecologic oncologist in the Division of Gynecologic Oncology and the Department of Obstetrics and Gynecology at the Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, a Dignity Health Member.

This study was initially developed in 2007, with 52 patients enrolled for the Phase II clinical trial between December 2007 and November 2009.

Patients were given 50 milligrams of selumetinib orally twice daily. Of those participants, eight had a measurable decrease in tumor size, seven had partial responses and 34 patients saw their tumors stabilize.
Advertisement

The findings suggest that inhibitors of the MAPK pathway warrant further investigation in patients with low-grade ovarian cancer.

"There just aren't very good treatments for low-grade ovarian cancer, so this discovery opens up a lot of new exciting possibilities for us," Dr. Farley said.

He added that Phase III of this trial is scheduled to begin in the next few weeks, with that trial to be the "definitive test" before the treatment becomes available to the general population.

The findings have been published in latest edition of The Lancet Oncology.

Source: ANI
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Ovarian Cancer Cancer and Homeopathy Clinical Trials - Different Phases of the trial Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Meigs Syndrome Ovarian Pain 

Recommended Reading
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of ....
Olaparib Effective in Treating Relapsed Ovarian Cancer
Treatment with Olaparib showed a significant improvement in the progression-free survival rate ......
Research Says Targeted Agent Selumetinib Shows Promise in Biliary Cancer
A multi-institutional clinical trial has revealed that the experimental agent selumetinib has shown ...
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Meigs Syndrome
Meigs'' syndrome is a medical condition with a triad of symptoms including benign ovarian tumor, asc...
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms ...
Ovarian Pain
Ovarian pain is caused due to various conditions like ovarian cysts, ovarian tumors, endometriosis, ...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use